European Journal of Clinical Pharmacology

, Volume 16, Issue 6, pp 375–379 | Cite as

Hypotensive action and side-effects of flutonidin in normal subjects

A double-blind controlled trial
  • P. Sala
  • S. M. Chierichetti
  • P. Ferrari


In a double blind study, planned as a 7×7 latin square, three oral doses of futonidin (0.5, 1, 2 mg), of clonidine (0.0075, 0.150, 0.300 mg) and of a placebo were administered to 7 normal volunteers on 7 different treatment days, with an interval of 3 days. On each treatment day sitting blood pressure, heart rate and reaction time were measured, and sedation and dry mouth evaluated before and 1, 2, 3, 4, 6, and 8 h after administration. The placebo did not modify the basal value of any variable. Flutonidin and clonidine produced dose-related effects on blood pressure, heart rate, sedation and dry mouth, but did not influence reaction time. Analysis of the dose-response curves demonstrated that the effect of flutonidin was one-fifth to one-twelfth that of clonidine, depending on which variable was considered.

Key words

flutonidin clonidine hypertension side effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Laverty, R.: A comparison of the behavioural effects of some hypotensive imidazoline derivatives in rats. Eur. J. Pharmacol.9, 163–169 (1969)Google Scholar
  2. 2.
    Hoefke, W., Kobinger, W., Walland, A.: Relationship between activity and structure in derivatives of clonidine. Arzneim. Forsch. (Drug Res.)25, 786–793 (1975)Google Scholar
  3. 3.
    Marmo, E., Caputi, A. P., Rossi, F., Lampa, E., Giordano, L., Accarino, G.: Experimental analysis of some cardiovascular effects of St 600, clonidine (St 155) and guanabenz (BR 750). Agressologie18, 189–200 (1977)Google Scholar
  4. 4.
    Djawan, Von S., Mlczoch, J., Niederberger, M., Penner, E., Grabner, G.: Ein neues Antihypertensivum der Imidazolin-Reihe: 5-Fluor-2-Methyl-2-Imidazolidinylidenbenzamin-Monohydrochlorid (St 600, Fluronidin): I. Haemodynamische Untersuchungen in Ruhe und unter Belastung. Wien. Klin. Wochenschr.88, 199–206 (1976)Google Scholar
  5. 5.
    Harvald, B.: Within-patient comparisons between different anty-hypertensive drugs. Clin. Sci. Mol. Med.51, 571s-573s (1976)Google Scholar
  6. 6.
    Kho, T. L., Zaal, G. A., Wester, A., De Leeuw, P. W., Birkenhäger, W. H.: Haemodynamic and endocrine changes during antihypertensive treatment with clonidine and its derivative St 600. Clin. Sci. Mol. Med.51, 641s-643s (1976)Google Scholar
  7. 7.
    Brunner, H. von, Djawan, S., Dorda, W., Penner, E., Grabner, G.: Ein neues Antihypertensivum der Imidazolin-Reihe: 5-Fluor-2-Methyl-Imidazolidinylidenbenzamin-Monohydroclorid (Flutonidin). Arzneim. Forsch. (Drug Res.)27, 1599–1604 (1977)Google Scholar
  8. 8.
    Bock, K. D., Heimsoth, V., Merguet, P., and Schoenermark, J.: Klinische und Klinisch-experimentelle Untersuchungen mit einer neuen blutdrucksenkenden Substanz, Dichlorophenylaminoimidazolin. Dtsch. Med. Wochenschr.91, 1761–1771 (1966)Google Scholar
  9. 9.
    Michel, D., Zimmerman, W., Nasschi, A., Seraphin, P.: Erste Beobachtungen über einen antihypertensive Effect von 2-(2,6 dichlorophenylamino)-2-imidazolin-hydrochloride am Menschen. Dtsch. Med. Wochenschr.91, 1540–1547 (1966)Google Scholar
  10. 10.
    Dollery, C. T., Davies, D. S., Draffan, G. H., Dargie, H. J., Dean, C. R., Reid, J. L., Clare, R. A., Murray, S.: Clinical pharmacology and pharmacokinetics of clonidine. Clin. Pharmacol. Ther.19, 11–17 (1976).Google Scholar
  11. 11.
    Cochran, W. G., Cox, G. M.: Double grouping: LatinSquare. In: Experimental designs. J. Wiley, (ed.), pp. 117–127. New York: John Wiley 1966Google Scholar
  12. 12.
    Edwards, A. L.: Comparing each treatment with a control. In: Experimental design in psychological research, pp. 148–150. New York: Holt, Rinehart and Winston 1968Google Scholar
  13. 13.
    Finney, D. I.: Symmetrical designs for parallel line assays. In Statistical method in biological assay, pp. 139–163. London: Charles Griffin 1964Google Scholar
  14. 14.
    Modell, W., and Houde, R. W.: Factors influencing clinical evaluation of drugs. J. Am. Med. Assoc.167, 2190–2197 (1958)Google Scholar
  15. 15.
    Reid, J. L., Wing, L. M. H., Mathias, C. J., Frankel, H. L., Neill, E.: The central hypotensive effect of clonidine. Studies in tetraplegic subjects. Clin. Pharmacol. Ther.21, 375–381 (1977)Google Scholar
  16. 16.
    Davies, D. S., Wing, L. M. H., Reid, J. L., Neill, E., Tippett, P., Dollery, C. T.: Pharmacokinetics and concentration effect relationship of intravenous and oral clonidine. Clin. Pharmacol. Ther.21, 593–601 (1977)Google Scholar
  17. 17.
    Keränen, A., Nykänen, S., Taskinen, J.: Pharmacokinetics and side-effects of clonidine. Eur. J. Clin. Pharmacol.13, 97–101 (1978)Google Scholar
  18. 18.
    Rand, M. J., Rush, M., and Wilson, S.: Some observations on the inhibition of salivation by ST 155. Eur. J. Pharmacol.5, 168–172 (1969)Google Scholar
  19. 19.
    Delbarre, B., and Schmitt, H.: A further attempt to characterize sedative receptors activated by clonidine in chickens and mice. Eur. J. Pharmacol.22, 355–359 (1973)Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • P. Sala
    • 1
  • S. M. Chierichetti
    • 1
  • P. Ferrari
    • 2
  1. 1.Department of Clinical ResearchInstituto De AngeliMilanItaly
  2. 2.Department of BiometryInstituto De AngeliMilanItaly

Personalised recommendations